PPAR agonists (elafibranor and lanifibranor) and semaglutide reached phase III clinical trials for the clinical treatment of MASLD and were reported to have a positive response in hepatic steatosis, MASH and fibrosis [49, 85, 140]. Here, PPARA is linked to fatty liver disease.